KRRO

Healthcare Biotechnology

Korro Bio, Inc.

$9.97

+0.33 +3.42% today

Price History

Not enough data

Key Stats

Market Cap

146.81M

Avg Volume

155,883

EPS

-$9.88

52W High

$55.89

52W Low

$5.20

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.24

P/B Ratio

1.42

P/S Ratio

61.64

EV/EBITDA

-1.00

EV/Revenue

31.06

Margins

Gross Margin 0.0%

Operating Margin (3228.3%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(97.7%)

Return on Assets

(28.0%)

Liquidity & Leverage

Current Ratio

9.55

Quick Ratio

9.11

Debt / Equity

0.41

Total Cash

115.04M

Total Debt

42.21M

About

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.